Since some of the most modern ion therapy facilities are offering or considering the irradiation with alternative ion beams, beyond proton and carbon, it has raised new attention the need for a proper description of these beams, in order to exploit their use for specific applications. In particular, helium and oxygen beams are presently available in the research cave of the Heidelberg Ion therapy facility (HIT). We developed and integrated in TRiP98, our research treatment planning system, specific beam models for these ions, which have been validated experimentally on different levels. For the Helium beam a semiempirical model for dose deposition and fragmentation was implemented, by modification of algorithms conventionally used in space radiation transport studies, translated to the typical therapeutic range of energies [1]. For Oxygen beam, the standard transport model of TRiP98 was tuned on recent attenuation experiments and the fragmentation cascade has been improved using the latest beam models of the low-lying ions. Several treatment planning tests have been performed, showing no universal indications but rather selective advantages of the different beams, and revealing for example a considerable convenience of using Helium beams in specific configurations [2], or proposing combination of different ions [3]. Experimental verification has been performed for both ion beams at the experimental room of HIT, analyzing different endpoints: basics physics data, delivered 3D physical dose distribution and biological effect. Monoenergetic and extended target irradiations of different extensions with single and double opposed fields have been verified. In the case of oxygen beams, considering that its main importance is related to a possible indication for partially hypoxic tumors, the biological verification was extended beyond the RBE weighted dose effect, but also including the OER effect. As previously obtained with carbon ions [4], the kill-painting method, allowing to restore an homogeneous survival level on a differently oxygenated target, was verified with oxygen beams. It is found that with the latter ion beams, for a partially hypoxic target an inversion of the relative profile occurs, as compared to a normoxic case, with a slightly reduced normal tissue damage for same cell killing in the target than with the carbon irradiation. The demand for personalized medicine is increasing, and considering that the population suffering from chronic diseases (i.e. cancer, Alzeihmer) is continuously growing it is expected that the consumption of molecular diagnostic products and radiotherapeutics will continue to increase. In this scenario, TRIUMF and its fleet of proton accelerators ranging from 13 to 500 MeV is offering a unique environment for scientists to enable the production of isotopes with potential applications in molecular imaging or radiotherapy. A multidisciplinary program involving target design, isotope production and radiopharmaceutical chemistry has emerged in the Division of Life Sciences to facilitate and accelerate the translation from bench-to-bedside. A brief overview of the recent efforts related to the production and applications of medical isotopes at TRIUMF will be presented. Comprehensive studies have been conducted to improve the production of conventional PET isotopes by a better understanding of the physical phenomenon occurring inside the target during beam irradiation. Feasibility of the production, from liquid targets, of radiometals (i.e. At will be mentioned. Novel radiolabeling strategies and technologies have recently emerged to prepare radiopharmaceuticals and will be discussed. Isotopic exchange reactions are getting popular to rapidly and efficiently synthesize PET imaging probes. Click chemistry is also representing an attractive approach to radiolabel molecules because of its simple process, short reaction times and clean product synthesis. Microfluidic devices bear great promises in the field of radiochemistry as it is expected that they will allow faster reaction rate, exquisite reaction selectivity, reduced reagent consumption, and possibly revisit the hot-lab concept. An overview of the tracer development performed at TRIUMF (e.g. cysteine transporter, angiogenesis) will be presented. Finally, within the framework of the MEDICIS-PROMED consortium, a collaboration between TRIUMF and the Institute of Translational Molecular Imaging (ITMI) at the University Hospital of Geneva and the Laboratory of Bioorganic Chemistry and Molecular Imaging at EPFL will soon take place. This presentation will conclude with a short summary of our ambitious project on the development of dual modality molecular probes for ovarian cancer and their preclinical validations in animal models. Purpose: The main purpose of the present work is to evaluate the effects of gold nanoparticles (GNPs) in different sizes and concentrations on cancer cells which undergo treatment with photon therapy.
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